Cannabis Law Report

AUGUST 12, 2021

loss per share, during the same period in 2020 (after including non-cash share-based compensation expense of $11.4 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Net loss for the six months ended 30 June 2021 was $30.2

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

NORML

JANUARY 4, 2019

Separate provisions in the bill exclude cannabidiol from the federal definition of marijuana, permit VA doctors to authorize medical cannabis access to qualified patients, and remove undue federal barriers to clinical trial research to better assess the safety and efficacy of medical cannabis. NH resident? GA resident?

Legislation 127

Legislation Clinical Trials Research and Development Access 127

Cannabis Law Report

OCTOBER 15, 2021

DNA variations or polymorphisms) in patients with African ancestry. The KGA is a proprietary computational platform built in-house at Goldfinch Bio to identify genetic and environmental causes of kidney diseases in patient subsets and the associated biological targets for therapeutic intervention. Poster Number: INFO37.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

JULY 9, 2021

Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. On November 3, 2020, Oregon became the first state to decriminalize psilocybin for recreational purposes. 360bbb-0a(a)(2).

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

OCTOBER 13, 2021

Filed in support of the Company’s CYB004 pre-clinical development program, the PCT filing serves to increase the Company’s library of drug delivery modalities directed to optimal delivery of psychedelics and further strengthens Cybin’s growing IP portfolio. Vigorous scientific research and clinical trials are needed.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

JUNE 25, 2021

billion in 2020 to $1.61 The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region. Global Skin Cancer Drugs Historic Market, 2015-2020, $ Billion. Skin Cancer Drugs Market Size And Growth.

Research and Development 84

Research and Development Therapy Pharmaceutical Clinical Trials 84

The Cannigma

AUGUST 26, 2021

percent), according to the United Nations World Drug Report for 2020.In In addition, a survey published in July 2020 found that 41% of Australians support cannabis legalization, and 37% are opposed. This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Key Priorities for 2020.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

JULY 14, 2021

ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. In one particular group, all patients showed consistent results across multiple genomic analyses. The Federal Controlled Substances Act classifies “marihuana” as a Schedule I drug. federal law.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

MAY 29, 2022

In 2020, Oregon became the first locale to decriminalize psilocybin and legalize it for therapeutic use on a statewide basis. Clinical Trials and Human Subject Protections. FDA’s approval of an IND will also require sufficient evidence that the trial will be safe for human subjects. 20, 2020), [link]. [8]

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 649, 654 (2020). 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. 2 × 2. . § Mitchell et al., 13 × 13.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen.

CBD 98

CBD THC Conditions Medicine 98

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen.

CBD 52

CBD THC Conditions Medicine 52

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

JUNE 4, 2021

He practiced as a British Physiotherapist for over fifteen years, running clinics that specialized in integrative pain management and injury rehabilitation, treating over 40,000 patients. Based on the way it’s produced, Delta 8-THC should be batch tested to ensure consumer safety.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

Project CBD

FEBRUARY 28, 2023

This was somewhat less than the nearly 37% decline seen in 2020. decline from 2020. Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. million on these products.

CBD 144

CBD Seed-To-Sale Food Access 144

The Cannigma

MARCH 12, 2021

But sometimes one unintended consequence of adult-use legalization is that the market no longer caters to medical patients. So, you have this attempt to legitimize healthcare and to adopt standards, to do things in a more scientific way, and in a more credible way, for patients and for industry. It’s a non-trivial issue.

Legalization 128

Legalization Patients Education Dispensary 128

Cannabis Law Report

NOVEMBER 26, 2021

Corporate and Clinical Development Highlights Include: Completed Patient Enrollment in Phase III Psoriasis Study – The Phase III Comfort™ study completed patient enrollment. million during the nine months ended September 30, 2020. million for the same period in 2020. Topline results are expected in Q1 2022.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Cannabis Law Report

NOVEMBER 13, 2019

Denmark is already leading the way by launching a Big Pharma modelled 4-year medical marijuana trial in early 2018, following a unanimous vote in Parliament. Coupled with transit time and testing in the EU, delays could impact the shelf-life of product patients will receive,” he said. Arundati Dandapani. Founder and CEO, . Generation1.ca.

Clinical Trials 78

Clinical Trials Research and Development Cultivation Patients 78

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. The review, however, did not cover patient access to medicinal cannabis. The states’ situation varies substantially.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

NOVEMBER 10, 2021

as well as to support Good Laboratory Practices (GLP) toxicology, safety studies and preclinical efficacy studies. The NIH has contracted with a clinical research organization to conduct additional pre-clinical efficacy studies and procured a device to be used with the manufactured GMP drug product for preclinical and clinical studies.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

AUGUST 30, 2019

Ballot initiative campaigns to approve adult-use and medical cannabis, respectively, moved closer to appearing on the 2020 ballot in Arizona and Idaho, while a similar effort to put the issue of adult-use cannabis to Ohio voters has met with legal challenges from the State Election Board. Governor Ducey (R-AZ) opposes legalization.

Banking 45

Banking Research and Development Legislation Programs 45

Canna Law Blog

MAY 7, 2020

At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. As of December 2019, there are only two patients on the coveted list and no new entrants are permitted.

DEA 70

DEA Research and Development Cultivation Supply Chain 70

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Published in late 2020, Brian has since appeared on dozens of media outlets, including Joe Rogan’s podcast, CNN, and Vice.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

OCTOBER 17, 2019

Many of these are meant to address public safety risks, especially for young people. It’s big business,” says Jackim, noting that there are 200,000 patients in the state who hold cards allowing them to purchase cannabis for medical purposes. alcoholic beverages, caffeine, and tobacco).

Law 40

Law Seed-To-Sale Hemp Recreational 40